Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Laboratory Medicine

Official Journal of the German Society of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Schuff-Werner, Peter

Ed. by Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Bietenbeck, Andreas / Conrad, Karsten / Findeisen, Peter / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / Meyer, Alexander von / Nebe, Carl Thomas / Orth, Matthias / Röhrig-Herzog, Gabriele / Sack, Ulrich / Steimer, Werner / Weber, Thomas / Wieland, Eberhard / Winter, Christof / Zettl, Uwe K.

IMPACT FACTOR 2018: 0.389

CiteScore 2018: 0.22

SCImago Journal Rank (SJR) 2018: 0.156
Source Normalized Impact per Paper (SNIP) 2018: 0.089

Print + Online
See all formats and pricing
More options …
Volume 40, Issue 3


Correlation between severity of migraine attacks and IgE level in peripheral blood

Maryam Hassanpour Moghadam
  • Corresponding author
  • Department of Pharmacodynamics, Pharmaceutical Research Center, School of pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hamidreza Ardalani
  • Department of Horticultural Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Alireza Alehashemi / Mahboobeh Adami Dehkordi / Mojtaba Meshkat
Published Online: 2016-05-12 | DOI: https://doi.org/10.1515/labmed-2016-0012


Background: The correlation between allergic diseases and migraine is partially due to a better understanding of inflammatory mediators with vasoactive function that play an important role in these diseases. This study aimed to evaluate the correlation between allergic sensitization and severity of migraine.

Methods: This study was carried out on 212 patients who suffered from migraine headache in a university hospital in Mashhad, Iran. All of these patients were evaluated for allergic rhinitis (AR) by measuring the IgE level in peripheral blood and assessing the clinical symptoms of AR. Prevalence of AR in migraine patients and degree of allergic sensitization was assessed in this study.

Results: The prevalence of AR in migraine patients was 78.30%. Total IgE levels in the peripheral blood in migraine patients with AR were found to be significantly (p<0.0001) higher than those without migraines. There was a significant difference between severity of AR (higher level of IgE) and severity of migraine attacks (p<0.0001), but there was not any significant difference between severity of AR and other factors.

Conclusions: We propose that inflammatory mediators play a key role in triggering migraine attacks. Thus, effective treatment of AR in migraine patients plays an important role in treatment and prevention of migraine headaches.

Keywords: allergic rhinitis; IgE; migraine


  • 1.

    Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30:1065–72.Google Scholar

  • 2.

    Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, et al. Migraine headache is present in the aura phase: a prospective study. Neurology 2012;79:2044–9.Google Scholar

  • 3.

    Foroozan R, Cutrer FM. Transient neurologic dysfunction in migraine. Neurol Clin 2009;27:361–78.Web of ScienceGoogle Scholar

  • 4.

    Etrusic I, Zidverc-Trajkovic J, Podgorac A, Sternic N. Underestimated phenomena: higher cortical dysfunctions during migraine aura. Cephalalgia 2013;33:861–7.Google Scholar

  • 5.

    Theriot JJ, Toga AW, Prakash N, Ju YS, Brennan KC. Cortical sensory plasticity in a model of migraine with aura. J Neurosci 2012;32:15252–61.Google Scholar

  • 6.

    Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006;46:1552–64.Google Scholar

  • 7.

    Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol 2007;7:383–93.Google Scholar

  • 8.

    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793–803.Google Scholar

  • 9.

    Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963–74.Google Scholar

  • 10.

    Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 2008;28:531–40.Web of ScienceGoogle Scholar

  • 11.

    Battista J, Badcock DR, McKendrick AM. Migraine increases centre-surround suppression for drifting visual stimuli. PLoS One 2011;6:181–98.Google Scholar

  • 12.

    Hargreaves RJ, Shepheard SL. Pathophysiology of migraine: new insights. Can J Neurol Sci 1999;26:12–9.Google Scholar

  • 13.

    Welch KM. Pathogenesis of migraine. Semin Neurol 1997;17:335–41.Google Scholar

  • 14.

    Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerine) triggers genuine migraine attacks. Eur J Neurol 1994;1:73–80.Google Scholar

  • 15.

    Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998;18:27–32.Google Scholar

  • 16.

    Omenaas E, Bakke P, Elsayed S, Hanoa R, Gulsvik A. Total and specific serum IgE levels in adults: relationship to sex, age and environmental factors. Clin Exp Allergy 1994;24:530–9.Google Scholar

  • 17.

    Scarupa MD, Economides A, White MV, Kaliner MA. Rhinitis and rhinologic headaches. Allergy Asthma Proc 2004;25:101–5.Google Scholar

  • 18.

    Kemper RH, Meijler WJ, Korf J, Ter Horst GJ. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalgia 2001;21:549–57.Google Scholar

  • 19.

    De Souza Carvalho D, Fragoso YD, Coelho FM, Pereira MM. Asthma plus migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antagonist. Headache 2002;42:1044–7.Google Scholar

  • 20.

    Selmaj K. Histamine release from leucocytes in migraine. Cephalalgia 1983;3:37–40.Google Scholar

  • 21.

    Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia 2006;8:91–6.Google Scholar

  • 22.

    Lucas C, Romatet S, Mekiès C, Allaf B, Lantéri-Minet M. Stability, responsiveness, and reproducibility of a visual analog scale for treatment satisfaction in migraine. Headache 2012;52:1005–18.Google Scholar

  • 23.

    Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol 2010;15:1–16.Google Scholar

  • 24.

    Mitsikostas DD, Tsaklakidou D, Athanasiadis N, Thomas A. The prevalence of headache in Greece: correlations to latitude and climatological factors. Headache 1996;36:168–73.Google Scholar

  • 25.

    Turner MK, Hooten WM, Schmidt JE, Kerkvliet JL, Townsend CO, Bruce BK. Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. Pain Med 2008;9:979–84.Web of ScienceGoogle Scholar

  • 26.

    Knutsen KV, Brekke M, Gjelstad S, Lagerlov P. Vitamin D status in patients with musculoskeletal pain, fatigue and headache: a cross-sectional descriptive study in a multi-ethnic general practice in Norway. Scand J Prim Health Care 2010;28:166–71.Web of ScienceGoogle Scholar

  • 27.

    Ayatollahi SM, Khosravi A. Prevalence of migraine and tension-type headache in primary-school children in Shiraz. East Mediterr Health J 2006;12:809–17.Google Scholar

  • 28.

    Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ, et al. Aids for management of common headache disorders in primary care. J Headache Pain 2007;8:3–47.Google Scholar

  • 29.

    Davey G, Sedgwick P, Maier W, Visick G, Strachan DP, Anderson HR. Association between migraine and asthma: matched case-control study. Br J Gen Pract 2002;52:723–7.Google Scholar

  • 30.

    Martin VT, Taylor F, Gebhardt B, Tomaszewski M, Ellison JS, Martin GV, et al. Allergy and immunotherapy: are they related to migraine headache? Headache 2011;51:8–20.Google Scholar

  • 31.

    Aurora S, Winner P, Freeman M, Spierings E, Heiring J, DeGryse R, et al. Onabotulinum toxin a for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51:1358–73.Google Scholar

  • 32.

    Straube A, Gaul C, Förderreuther S, Kropp P, Marziniak M, Evers S, et al. Therapy and care of patients with chronic migraine. Nervenarzt 2012;83:1600–8.Google Scholar

  • 33.

    Diener HC, Dodick DW, Aurora SK, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804–14.Google Scholar

  • 34.

    Aurora SK, Kulthia A, Barrodale PM. Mechanism of chronic migraine. Curr Pain Headache Rep 2011;15:57–63.Web of ScienceGoogle Scholar

About the article

Received: 2016-02-01

Accepted: 2016-03-16

Published Online: 2016-05-12

Published in Print: 2016-06-01

Citation Information: LaboratoriumsMedizin, Volume 40, Issue 3, Pages 215–219, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/labmed-2016-0012.

Export Citation

©2016 by De Gruyter.Get Permission

Comments (0)

Please log in or register to comment.
Log in